Juniper Vale: Hey — rough week on my end, lots of coffee, but I have a feeling you're about to make it interesting.
Finn Brooks: I am absolutely about to make it interesting, I've been waiting to say this out loud — I want to give you a number first, just cold. Fifty-nine percent.
Juniper Vale: Okay, fifty-nine percent of what, and why do you look like you won something?
Finn Brooks: Because — okay, so Merck just got FDA approval, July 16th, for a drug called Lipfendra. First once-daily oral PCSK9 inhibitor ever cleared in the U.S. And in the CORALreef HeFH trial, that fifty-nine percent is the placebo-adjusted LDL drop at week twenty-four. The other trial, CORALreef Lipids, was fifty-six. Either way it's — dude, that's a pill doing what used to require a needle every two weeks.
Juniper Vale: And the needle thing matters more than people realize — Repatha, Praluent, they've been sitting there for years with good data and patients just won't do the injections.
Finn Brooks: Exactly, and here's the plain-language version of why this even works — your liver has these receptors that grab LDL out of your blood. But normally PCSK9, this protein, runs around destroying those receptors. It's basically a disposal crew trashing the very machinery that cleans your blood. Lipfendra blocks PCSK9, the disposal crew never shows up, receptors stay alive, LDL gets cleared. That's it. One in four adults on statins still can't hit their LDL target — that's around twenty million people — and this is the first pill that can actually reach them.
Juniper Vale: Okay that analogy actually works. But I do want to get into what 'approved' means here, because there's a piece of this story that's — it's not a flaw exactly, but it's a thing.
Finn Brooks: Wait, a thing like — a gap in the data thing?
Juniper Vale: The FDA approved Lipfendra on a surrogate endpoint. Meaning the approval rests on the LDL number — that fifty-six, fifty-nine percent drop — and not on evidence that it actually prevents heart attacks or strokes. Those confirmatory outcomes trials? Still required. Still pending. They don't exist yet.
Finn Brooks: Okay but — I mean, LDL causes heart disease, right, so lower LDL equals less heart disease, that's just... that's the mechanism.
Juniper Vale: That's exactly the argument, and it's not wrong — but it's also not proven for this specific molecule yet. Repatha and Praluent, the injectables, they have years of cardiovascular outcomes data. Actual trials. Heart attacks prevented, strokes prevented, numbers attached to real lives. Lipfendra is approved for that same high-risk population — including people with heterozygous familial hypercholesterolemia, HeFH, which is a genetic condition where your cholesterol is dangerous from birth — and we are asking them to trust the mechanism rather than the evidence. That's a real gap.
Finn Brooks: The HeFH piece — wait, that's the group where statins often aren't enough to begin with, so they're already the highest-stakes patients and they're getting the drug with the thinnest outcomes file.
Juniper Vale: Right — and the convenience case is real, I'm not dismissing it, millions of people won't do injections and that matters. But is a dramatic LDL number the same thing as a saved life? That's not settled yet. And the part that makes this murkier — we'll get there — is who's actually driving the timeline on that question.
Finn Brooks: And who's driving the timeline is — okay, that's the part I keep getting stuck on. Because Lipfendra got the FDA Commissioner's National Priority Voucher. Which is supposed to be for drugs that are urgent for public health or national security. And then you look at when Keytruda's patent protection starts expiring — 2028 — and Merck suddenly needs a blockbuster successor. I'm not saying those two facts are connected. I'm just saying they're... very close together.
Juniper Vale: Louise Chen at Scotiabank projected tens of billions in peak sales. Tens.
Finn Brooks: Right — but the part that doesn't fit the cynical read is the 58-year-old in cardiac rehab. Like, picture her: she's two hours from her cardiologist, she's been told she needs a PCSK9 inhibitor, biweekly injections aren't happening, and for her a daily pill isn't a convenience story, it's actually the only story. That's real.
Juniper Vale: No, that's real. I'm not arguing against her.
Finn Brooks: But the uncomfortable thing is — broader adoption means more people exposed to a drug whose cardiovascular benefit is still unconfirmed. So the same thing that helps her is also the thing that scales the risk before we have the outcomes data. I'm not saying it's corrupt, I genuinely am not, I'm just saying those two things are — wait, actually — they're basically impossible to separate right now.
Juniper Vale: That's the honest version of it. The voucher sped up a review process, not the confirmatory trial. Those are still coming. So the question is whether 'expedited' means 'ready' — and the answer is not quite the same thing.
Finn Brooks: Did the voucher exist because patients needed this urgently, or because Merck needed a Keytruda successor? I don't know. I genuinely don't know.
Juniper Vale: I'll be honest with you — I keep landing in the same uncomfortable place. The LDL number is real. The convenience is real. But the confirmatory cardiovascular outcomes trial is still out there somewhere, pending, and by the time those results come in, Lipfendra will already be in millions of medicine cabinets. And if that trial disappoints — if the heart attack and stroke data doesn't follow the LDL drop the way everyone expects — patients and physicians and payers have already built their whole approach around it. There's no clean exit from that.
Finn Brooks: So I was right that it's a pill revolution. I just may have buried the footnote.
Juniper Vale: That's actually the most accurate thing either of us has said. The FDA made a bet on a surrogate endpoint — that the mechanism is established enough to skip waiting for outcomes proof. Maybe that's medicine moving smart. Maybe it's just medicine moving fast. The confirmatory trial is the only thing that'll tell us which one it was.
Finn Brooks: Yeah. Good talk — I mean, genuinely, that one sat with me.
